
Valuation analysis

- P/E
- Price
- High
- Median
- Low
- P/B
- Price
- High
- Median
- Low
- P/S
- Price
- High
- Median
- Low
- Dividend Yield
- Price
- High
- Median
- Low
Institutional View & Shareholder
Analyst Ratings
- Price--
- Highest--
- Lowest--
以下为海豚君整理的 $Baidu(BIDU.US) 2025 财年第三季度财报电话会议纪要, $BIDU-SW(09888.HK) 财报解读请移步《 百度,猛贴 AI 讲故事,真能救活自己吗?》一、财报核心信息回顾 1. $BIDU-SWR(89888.HK) AI 收入占比已达 40%:三季度,直接与 AI 相关的收入实现近 100 亿,这已达到总营收的 40%...
$Baidu(BIDU.US) released its Q3 results after Hong Kong market hours on 18 November 2025. Overall, the performance met expectations. The detailed disclosure of AI revenue demonstrates the company's ea...
$Recursion Pharmaceuticals(RXRX.US) Recursion Pharmaceuticals (RXRX.US) vs. XtalPi (2228.HK)$XTALPI(02228.HK) In-depth competitive benchmarking analysis: Comparison of technological pathways, business...
The following are the minutes of the 3Q25 earnings call for $Meta Platforms(META.US) organized by Dolphin Research. For an interpretation of the earnings report, please refer to "Meta: AI Investment '...
$Lemonade(LMND.US) The following answer systematically breaks down how Lemonade (LMND.US) integrates AI across the entire insurance value chain, its current outputs, and how it is reflected in financi...



